Research synthesis only; not medical advice. Adverse-event reporting obligations vary by jurisdiction and depend on the product's regulatory status, the reporter's identity (patient, health-care professional, manufacturer, investigator), and the relationship of the event to the product. This page explains pharmacovigilance principles; it does not provide a reporting form or therapeutic advice.
Definitions
| Term | Definition (ICH E2A / CIOMS) |
|---|---|
| Adverse event (AE) | Any untoward medical occurrence in a patient or clinical investigation subject administered a product; does not necessarily have a causal relationship |
| Adverse drug reaction (ADR) | A response to a drug that is noxious and unintended; implies at least a reasonable possibility of causality |
| Serious adverse event (SAE) | Any AE that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or requires intervention to prevent permanent impairment |
| Unexpected adverse event | An AE whose nature or severity is not consistent with the applicable product information (e.g., prescribing information, investigator's brochure) |
| Suspected unexpected serious adverse reaction (SUSAR) | An SAE that is suspected to be related to the product and is unexpected; SUSARs require expedited reporting in clinical trials |
Pharmacovigilance systems
FDA
MedWatch (https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program): The primary system for voluntary reporting by health-care professionals and consumers, and mandatory reporting by manufacturers.
FAERS (FDA Adverse Event Reporting System): Database of all reported adverse events. Accessible via FDA public dashboard.
VAERS (Vaccine Adverse Event Reporting System): Cosponsored by FDA and CDC; is specific to vaccines, not peptide products.
EMA
EudraVigilance (https://www.ema.europa.eu/en/human-regulatory/research-development/pharmacovigilance/eudravigilance): The European system for reporting and analyzing suspected ADRs.
Individual Case Safety Report (ICSR): The structured report format used in EudraVigilance.
PRAC (Pharmacovigilance Risk Assessment Committee): EMA committee responsible for assessing and monitoring safety.
MHRA (UK)
Yellow Card Scheme (https://yellowcard.mhra.gov.uk): Reporting system for ADRs, medical device incidents, and defective medicines.
WHO
VigiBase (https://www.who-umc.org/vigibase/vigibase/): WHO global database of ICSRs maintained by the Uppsala Monitoring Centre.
MedDRA coding
Medical Dictionary for Regulatory Activities (MedDRA) is the standardized terminology for coding adverse events. Events are coded to a "lowest level term" (LLT), which maps up through "preferred term" (PT), "high level term" (HLT), "high level group term" (HLGT), and "system organ class" (SOC).
Example:
LLT: "Feeling cold"
PT: "Chills"
HLT: "Temperature sensation disorders"
HLGT: "Neurological disorders NEC"
SOC: "Nervous system disorders"
Accurate coding is essential for signal detection: a PT of "Injection site erythema" and "Injection site rash" may represent the same clinical finding but be coded differently.
Reporting obligations
Manufacturers
Expedited and periodic reporting duties are actor-, product-, event-, and jurisdiction-specific. For example, US FDA and EU pharmacovigilance regimes include 15-day categories for specified serious and unexpected suspected adverse reactions; the applicable rule defines the clock start, recipient, follow-up, and exceptions. This is not a universal reporting deadline.
Aggregate safety data submitted as Periodic Benefit-Risk Evaluation Reports (PBRERs) per ICH E2C(R2).
Post-approval safety studies may be required as a condition of marketing authorization.
Health-care professionals
Voluntary in most jurisdictions for non-serious events.
Mandatory or strongly encouraged for serious events, unexpected events, and events in special populations (pregnancy, pediatrics).
Some US states mandate reporting of specific events (e.g., adverse events following immunization).
Clinical investigators
Investigators report SAEs to the sponsor immediately after learning of them, except events the protocol identifies as not requiring immediate reporting; the protocol and applicable jurisdiction define the operational deadline.
Reporting of non-serious AEs per protocol schedule.
Sponsor reporting of suspected unexpected serious adverse reactions follows the applicable regime. For example, EU and US frameworks use seven- and fifteen-day expedited categories in specified circumstances, but the actor, clock start, follow-up, and recipient differ. Those figures are not a global instruction.
Signal detection and risk management
Safety signals — information suggesting a new potentially causal association or a new aspect of a known association — are identified from:
Spontaneous reporting databases (FAERS, EudraVigilance)
Clinical trial data
Published literature
Observational studies
Disproportionality analysis compares the observed-to-expected ratio of a specific drug--event combination. The proportional reporting ratio (PRR) and the reporting odds ratio (ROR) are common metrics. A signal typically requires PRR ≥2, chi-square ≥4, and ≥3 cases.
Specific adverse events relevant to peptide products
| Category | Examples | Notes |
|---|---|---|
| Injection-site reactions | Erythema, pruritus, induration, pain, hematoma | Most common AE class for injectable peptide products; often mild |
| Immunogenicity | Anti-drug antibodies (ADA), neutralizing antibodies | Can affect efficacy and safety; required assessment per ICH S6 |
| Hypersensitivity | Urticaria, angioedema, anaphylaxis | Rare but potentially life-threatening |
| Local tolerability | Lipodystrophy (with repeated SC injections), scarring | Education on site rotation (if labeled) reduces risk |
| Systemic effects | Gastrointestinal (GLP-1 agonists), hypoglycemia (insulin), fluid retention (growth hormone) | Product-specific; detailed in prescribing information |
Sources
ICH Harmonised Tripartite Guideline. Clinical Safety Data Management: Definitions and Standards for Expedited Reporting (E2A). 1994. https://database.ich.org/sites/default/files/E2A_Guideline.pdf
ICH Harmonised Tripartite Guideline. Clinical Safety Data Management: Periodic Benefit-Risk Evaluation Report (E2C(R2)). 2012. https://database.ich.org/sites/default/files/E2C_R2_Guideline.pdf
ICH Harmonised Tripartite Guideline. Good Clinical Practice (E6(R2)). 2016. https://database.ich.org/sites/default/files/E6_R2_Addendum.pdf
ICH Harmonised Tripartite Guideline. Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals (S6(R1)). 2011. https://database.ich.org/sites/default/files/S6_R1_Guideline_0.pdf
FDA. Guidance for Industry: Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment. 2005. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/good-pharmacovigilance-practices-and-pharmacoepidemiologic-assessment
EMA. Guideline on Good Pharmacovigilance Practices (GVP). EMA/876333/2011. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/pharmacovigilance-post-authorisation/good-pharmacovigilance-practices-gvp
Uppsala Monitoring Centre. VigiBase — the WHO Global Database of Individual Case Safety Reports (ICSRs). https://www.who-umc.org/vigibase/vigibase/